The pharmaceutical industry is undergoing a major transformation, placing patients at the forefront of drug development like ...

In conclusion, a demerger, like any major pivot, is a high-stakes, high-value moment where everything matters. Reconnect to ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...

Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, ...

Many will celebrate having an extra hour in bed – perhaps forgetting how they lost an hour at the end of March when the ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Collaboration is a huge topic in healthcare today. The industry is evolving extremely fast, and while that brings with it plenty of opportunity, it also creates new challenges. How do businesses ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a ...